Patent: 7,727,954
✉ Email this page to a colleague
Summary for Patent: 7,727,954
| Title: | Drug depot implant designs |
| Abstract: | The present invention relates to novel drug depot implant designs for optimal delivery of therapeutic agents to subjects. The invention provides a method for alleviating pain associated with neuromuscular or skeletal injury or inflammation by targeted delivery of one or more therapeutic agents to inhibit the inflammatory response which ultimately causes acute or chronic pain. Controlled and directed delivery can be provided by drug depot implants, comprising therapeutic agents, specifically designed to deliver the therapeutic agent to the desired location by facilitating their implantation, minimizing their migration from the desired tissue location, and without disrupting normal joint and soft tissue movement. |
| Inventor(s): | McKay; William F. (Memphis, TN) |
| Assignee: | Warsaw Orthopedic, Inc. (N/A) |
| Application Number: | 11/734,618 |
| Patent Claims: | see list of patent claims |
Details for Patent 7,727,954
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Hoffmann-la Roche Inc. | ZENAPAX | daclizumab | Injection | 103749 | 12/10/1997 | ⤷ Try a Trial | 2026-04-13 |
| Janssen Biotech, Inc. | REMICADE | infliximab | For Injection | 103772 | 08/24/1998 | ⤷ Try a Trial | 2026-04-13 |
| Immunex Corporation | ENBREL | etanercept | For Injection | 103795 | 11/02/1998 | ⤷ Try a Trial | 2026-04-13 |
| Immunex Corporation | ENBREL | etanercept | For Injection | 103795 | 05/27/1999 | ⤷ Try a Trial | 2026-04-13 |
| Immunex Corporation | ENBREL | etanercept | Injection | 103795 | 09/27/2004 | ⤷ Try a Trial | 2026-04-13 |
| Immunex Corporation | ENBREL | etanercept | Injection | 103795 | 02/01/2007 | ⤷ Try a Trial | 2026-04-13 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
